ArticleScientific reports2025
Protective potential of tween 80-functionalized chitosan-selenium nanoparticles containing quercetin against cisplatin neurotoxicity in PC12 cells: an in vitro and network pharmacology study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Protective Effects of Selenium Nanoparticles Against Metal Toxicity.Biological trace element research · 2026Review
- Amorphous selenium nanoparticles: synthesis strategies and multifunctional applications.RSC advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cisplatin is a commonly used chemotherapy drug that improves survival in many cancer patients but often causes severe neurotoxicity. Quercetin, a flavonoid antioxidant, has neuroprotective properties that can reduce cisplatin-induced neurotoxicity, but its clinical application is limited by poor bioavailability. This study aimed to combine nanomedicine and network pharmacology to develop Tween 80-functionalized chitosan-selenium nanoparticles containing quercetin (Q-Tw-Cs@Se NPs) and evaluate their protective effects against cisplatin-induced neurotoxicity in PC12 cells. Q-Tw-Cs@Se NPs were synthesized in a core-shell structure and characterized for size, morphology, optical properties, and chemical composition. Hemocompatibility, scavenging activity, and reducing power were assessed. The protective effects of the nanoparticles against cisplatin-induced toxicity in PC12 cells, used as a neuronal cell model, were evaluated using MTT assays and flow cytometry. Furthermore, network pharmacology was employed to predict hub targets and probable cellular mechanisms responsible for the protective effects of the nanoparticles. Q-Tw-Cs@Se NPs had an average size of 110 nm, a zeta potential of + 11.5 mV, and a quercetin encapsulation efficiency of ~ 50%. Pre-exposure to Q-Tw-Cs@Se NPs (1.25 µg/mL) for 24 h increased cell viability from 50% to nearly 80% in PC12 cells treated with cisplatin at its IC50 concentration. The nanoparticles also inhibited cisplatin-induced apoptosis and necrosis. Network pharmacology analysis identified BCL2, CASP3, AKT1, EGFR, STAT3, TNF, HSP90AA1, CTNNB1, IL-1β, and BCL2L1 as main targets enriched in apoptotic regulation. Altogether, Q-Tw-Cs@Se NPs show potential as neuroprotective adjuvants to reduce cisplatin-induced neurotoxicity. However, further in vitro and in vivo studies are required to confirm their therapeutic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.